BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
BridgeBio Pharma Inc. (NASDAQ: BBIO ) is one of the stocks with explosive growth potential . On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue to $502.1 million. This was driven largely by the commercial success of its flagship product, Attruby. In Q4 alone, Attruby generated $146 million in net product revenue, reflecting a 35% increase over Q3. This growth was supported by 7,804 new patient starts and high levels of patient persistence. The company achieved significant clinical milestones with three positive Phase 3 readouts in late 2025: Encaleret for ADH1, BBP-418 for LGMD2I, and Infigratinib for achondroplasia. These successes position BridgeBio to transition from a single-product company to one with potentially six approved medicines by the end of its first decade. NDAs for both Encaleret and BBP-418 are expected in H1 2026, with US launches targeted for late 2026 or early 2027. Charles River Laboratories Internati
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific ConferenceGlobeNewswire
- BridgeBio Pharma (BBIO) had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an "outperform" rating on the stock.MarketBeat
- BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- BridgeBio Pharma (BBIO) had its price target raised by Morgan Stanley from $96.00 to $98.00. They now have an "overweight" rating on the stock.MarketBeat
- BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 3/4/26 - Form 144
- 3/3/26 - Form 4
- 2/27/26 - Form 144
- BBIO's page on the SEC website